海西新药招股 预计10月17日上市

Core Viewpoint - HaiXi Pharmaceuticals is set to conduct a global offering from October 9 to 14, 2025, issuing 11.5 million shares priced between HKD 69.88 and HKD 86.40 per share, with expected listing on the Hong Kong Stock Exchange on October 17, 2025 [1] Company Overview - The company is a commercial-stage pharmaceutical firm engaged in research, production, and sales, focusing on the fastest-growing and largest therapeutic areas in China [1] - HaiXi Pharmaceuticals has a product portfolio primarily consisting of generic drugs that cover digestive, cardiovascular, endocrine, neurological, and inflammatory diseases [1] - The company is also developing innovative drugs, including a potential first-in-class oncology drug, a first-in-class oral wAMD/DME/RVO drug, and two innovative drugs in preclinical stages targeting oncology and respiratory systems [1] Product Pipeline and Intellectual Property - As of now, HaiXi Pharmaceuticals has received approval for 15 generic drugs and has four innovative drugs under development [1] - The company has established a global patent portfolio consisting of 37 patents [1] Fund Utilization - Assuming an offering price of HKD 78.14 per share, the net proceeds from the global offering are expected to be approximately HKD 848 million [1] - The funds will be utilized for research and development, enhancing R&D capabilities, seeking collaborations, improving commercialization capabilities, upgrading R&D production systems, and working capital [1]